IL-21-Expressing Mesenchymal Stem Cells Prevent Lethal B-Cell Lymphoma Through Efficient Delivery of IL-21, Which Redirects the Immune System to Target the Tumor

Stem Cells and Development

Volumn 24, Issue 23, 2015, Pages 2808-2821

  Kim, Nayoun ^a,b   Nam, Young Sun ^a,b   Im, Keon Il ^a,b   Lim, Jung Yeon ^a,b   Lee, Eun Sol ^a,b   Jeon, Young Woo ^a   Cho, Seok Goo ^a,b  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b Department of Laboratory of Immune Regulation   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; RECOMBINANT INTERLEUKIN 21; INTERLEUKIN 21; INTERLEUKIN DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; B CELL LYMPHOMA CELL; CANCER GENE THERAPY; CANCER INCIDENCE; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DISSEMINATED CANCER; DRUG EFFECT; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; IMMUNE SYSTEM; LIVER METASTASIS; LIVER NODULE; MESENCHYMAL STEM CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; TUMOR IMMUNITY; VIRAL GENE THERAPY; ANIMAL; BAGG ALBINO MOUSE; CELL CULTURE; CYTOLOGY; GENETICS; IMMUNOLOGY; LYMPHOMA, B-CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; FEMALE; INTERLEUKINS; KILLER CELLS, NATURAL; LYMPHOMA, B-CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED BALB C;

EID: 84947421679     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2015.0103     Document Type: Article

References (57)

1. Parrish-Novak J, SR Dillon, A Nelson, A Hammond, C Sprecher, JA Gross, J Johnston, K Madden, W Xu, et al. (2000). Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63.
2. Mehta DS, AL Wurster and MJ Grusby. (2004). Biology of IL-21 and the IL-21 receptor. Immunol Rev 202:84-95.
3. Davis ID, K Skak, MJ Smyth, PE Kristjansen, DM Miller and PV Sivakumar. (2007). Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res 13:6926-6932.
4. Wang G, M Tschoi, R Spolski, Y Lou, K Ozaki, C Feng, G Kim, WJ Leonard and P Hwu. (2003). In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 63:9016-9022.
5. Croce M, R Meazza, AM Orengo, M Fabbi, M Borghi, D Ribatti, B Nico, B Carlini, V Pistoia, MV Corrias and S Ferrini. (2008). Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunol Immunother 57:1625-1634.
6. Daga A, AM Orengo, RM Gangemi, D Marubbi, M Perera, A Comes, S Ferrini and G Corte. (2007). Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. Int J Cancer 121:1756-1763.
7. Furukawa J, I Hara, H Nagai, A Yao, S Oniki and M Fujisawa. (2006). Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response. J Urol 176:1198-1203.
8. Ugai S, O Shimozato, K Kawamura, YQ Wang, T Yamaguchi, H Saisho, S Sakiyama and M Tagawa. (2003). Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 10:187-192.
9. He H, P Wisner, G Yang, HM Hu, D Haley, W Miller, A OHara, WG Alvord, CH Clegg, et al. (2006). Combined IL-21 and low-dose IL-2 therapy induces anti-Tumor immunity and long-Term curative effects in a murine melanoma tumor model. J Transl Med 4:24.
10. Davis ID, B Brady, RF Kefford, M Millward, J Cebon, BK Skrumsager, U Mouritzen, LT Hansen, K Skak, et al. (2009). Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 15:2123-2129.
11. Davis ID, BK Skrumsager, J Cebon, T Nicholaou, JW Barlow, NP Moller, K Skak, D Lundsgaard, KS Frederiksen, P Thygesen and GA McArthur. (2007). An openlabel, two-Arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res 13:3630-3636.
12. Thompson JA, BD Curti, BG Redman, S Bhatia, JS Weber, SS Agarwala, EL Sievers, SD Hughes, TA DeVries and DF Hausman. (2008). Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol 26:2034-2039.
13. Schmidt H, J Brown, U Mouritzen, P Selby, K Fode, IM Svane, GP Cook, DH Mollerup and PF Geertsen. (2010). Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res 16:5312-5319.
14. Petrella TM, R Tozer, K Belanger, KJ Savage, R Wong, M Smylie, S Kamel-Reid, V Tron, BE Chen, et al. (2012). Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J Clin Oncol 30:3396-3401.
15. Bhatia S, B Curti, MS Ernstoff, M Gordon, EI Heath, WH Miller, Jr., I Puzanov, DI Quinn, TW Flaig, et al. (2014). Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer 2:2.
16. Timmerman JM, JC Byrd, DJ Andorsky, RE Yamada, J Kramer, N Muthusamy, N Hunder and JM Pagel. (2012). A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin Cancer Res 18:5752-5760.
17. Hashmi MH and PJ Van Veldhuizen. (2010). Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkins lymphoma. Expert Opin Biol Ther 10:807-817.
18. Kim N and SG Cho. (2013). Clinical applications of mesenchymal stem cells. Korean J Intern Med 28:387-402.
19. Spaeth E, A Klopp, J Dembinski, M Andreeff and F Marini. (2008). Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 15:730-738.
20. Kidd S, E Spaeth, JL Dembinski, M Dietrich, K Watson, A Klopp, VL Battula, M Weil, M Andreeff and FC Marini. (2009). Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 27:2614-2623.
21. Gao P, Q Ding, Z Wu, H Jiang and Z Fang. (2010). Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett 290:157-166.
22. Gunnarsson S, D Bexell, A Svensson, P Siesjo, A Darabi and J Bengzon. (2010). Intratumoral IL-7 delivery by mesenchymal stromal cells potentiates IFNgammatransduced tumor cell immunotherapy of experimental glioma. J Neuroimmunol 218:140-144.
23. Ren C, S Kumar, D Chanda, J Chen, JD Mountz and S Ponnazhagan. (2008). Therapeutic potential of mesenchymal stem cells producing interferon-Alpha in a mouse melanoma lung metastasis model. Stem Cells 26:2332-2338.
24. Seo SH, KS Kim, SH Park, YS Suh, SJ Kim, SS Jeun and YC Sung. (2011). The effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activity. Gene Ther 18:488-495.
25. Studeny M, FC Marini, RE Champlin, C Zompetta, IJ Fidler and M Andreeff. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 62:3603-3608.
26. Loebinger MR, A Eddaoudi, D Davies and SM Janes. (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69:4134-4142.
27. Mueller LP, J Luetzkendorf, M Widder, K Nerger, H Caysa and T Mueller. (2011). TRAIL-Transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 18:229-239.
28. van Eekelen M, LS Sasportas, R Kasmieh, S Yip, JL Figueiredo, DN Louis, R Weissleder and K Shah. (2010). Human stem cells expressing novel TSP-1 variant have anti-Angiogenic effect on brain tumors. Oncogene 29:3185-3195.
29. Soleimani M and S Nadri. (2009). A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 4:102-106.
30. Lee JH, EJ Jeon, N Kim, YS Nam, KI Im, JY Lim, EJ Kim, ML Cho, KT Han and SG Cho. (2013). The synergistic immunoregulatory effects of culture-expanded mesenchymal stromal cells and CD4(+)25(+)Foxp3+ regulatory T cells on skin allograft rejection. PLoS One 8:e70968.
31. Ozaki K, K Kikly, D Michalovich, PR Young and WJ Leonard. (2000). Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci U S A 97:11439-11444.
32. de Totero D, R Meazza, S Zupo, G Cutrona, S Matis, M Colombo, E Balleari, I Pierri, M Fabbi, et al. (2006). Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 107:3708-3715.
33. Akamatsu N, Y Yamada, H Hasegawa, K Makabe, R Asano, I Kumagai, K Murata, Y Imaizumi, K Tsukasaki, et al. (2007). High IL-21 receptor expression and apoptosis induction by IL-21 in follicular lymphoma. Cancer Lett 256:196-206.
34. de Totero D, M Capaia, M Fabbi, M Croce, R Meazza, G Cutrona, S Zupo, F Loiacono, M Truini, M Ferrarini and S Ferrini. (2010). Heterogeneous expression and function of IL-21R and susceptibility to IL-21-mediated apoptosis in follicular lymphoma cells. Exp Hematol 38:373-383.
35. Gowda A, J Roda, SR Hussain, A Ramanunni, T Joshi, S Schmidt, X Zhang, A Lehman, D Jarjoura, et al. (2008). IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 111:4723-4730.
36. Sarosiek KA, R Malumbres, H Nechushtan, AJ Gentles, E Avisar and IS Lossos. (2010). Novel IL-21 signaling pathway up-regulates c-Myc and induces apoptosis of diffuse large B-cell lymphomas. Blood 115:570-580.
37. de Totero D, R Meazza, M Capaia, M Fabbi, B Azzarone, E Balleari, M Gobbi, G Cutrona, M Ferrarini and S Ferrini. (2008). The opposite effects of IL-15 and IL-21 on CLL B cells correlate with differential activation of the JAK/STAT and ERK1/2 pathways. Blood 111:517-524.
38. Ueda M, K Imada, A Imura, H Koga, M Hishizawa and T Uchiyama. (2005). Expression of functional interleukin-21 receptor on adult T-cell leukaemia cells. Br J Haematol 128:169-176.
39. Marzec M, K Halasa, M Kasprzycka, M Wysocka, X Liu, JW Tobias, D Baldwin, Q Zhang, N Odum, AH Rook and MA Wasik. (2008). Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 68:1083-1091.
40. Dien Bard J, P Gelebart, M Anand, Z Zak, SA Hegazy, HM Amin and R Lai. (2009). IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol 175:825-834.
41. Chamberlain G, K Wright, A Rot, B Ashton and J Middleton. (2008). Murine mesenchymal stem cells exhibit a restricted repertoire of functional chemokine receptors: comparison with human. PLoS One 3:e2934.
42. Edinger M, YA Cao, MR Verneris, MH Bachmann, CH Contag and RS Negrin. (2003). Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 101:640-648.
43. Poggi A, C Prevosto, AM Massaro, S Negrini, S Urbani, I Pierri, R Saccardi, M Gobbi and MR Zocchi. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 175:6352-6360.
44. Spaggiari GM, A Capobianco, S Becchetti, MC Mingari and L Moretta. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484-1490.
45. Peluso I, MC Fantini, D Fina, R Caruso, M Boirivant, TT MacDonald, F Pallone and G Monteleone. (2007). IL-21 counteracts the regulatory T cell-mediated suppression of human CD4+ T lymphocytes. J Immunol 178:732-739.
46. Li Y and C Yee. (2008). IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111:229-235.
47. Aravindaram K, PH Wang, SY Yin and NS Yang. (2014). Tumor-Associated antigen/IL-21-Transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma. Gene Ther 21:457-467.
48. Kim N, KI Im, JY Lim, EJ Jeon, YS Nam, EJ Kim and SG Cho. (2013). Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice. Ann Hematol 92:1295-1308.
49. Patel SA, JR Meyer, SJ Greco, KE Corcoran, M Bryan and P Rameshwar. (2010). Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 184:5885-5894.
50. Al-Khaldi A, N Eliopoulos, D Martineau, L Lejeune, K Lachapelle and J Galipeau. (2003). Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther 10:621-629.
51. Sun B, S Zhang, C Ni, D Zhang, Y Liu, W Zhang, X Zhao, C Zhao and M Shi. (2005). Correlation between melanoma angiogenesis and the mesenchymal stem cells and endothelial progenitor cells derived from bone marrow. Stem Cells Dev 14:292-298.
52. Martin FT, RM Dwyer, J Kelly, S Khan, JM Murphy, C Curran, N Miller, E Hennessy, P Dockery, et al. (2010). Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res Treat 124:317-326.
53. Khakoo AY, S Pati, SA Anderson, W Reid, MF Elshal, II Rovira, AT Nguyen, D Malide, CA Combs, et al. (2006). Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposis sarcoma. J Exp Med 203:1235-1247.
54. Qiao L, Z Xu, T Zhao, Z Zhao, M Shi, RC Zhao, L Ye and X Zhang. (2008). Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 18:500-507.
55. Ryu H, JE Oh, KJ Rhee, SK Baik, J Kim, SJ Kang, JH Sohn, E Choi, HC Shin, et al. (2014). Adipose tissuederived mesenchymal stem cells cultured at high density express IFN-beta and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett 352:220-227.
56. Ramasamy R, EW Lam, I Soeiro, V Tisato, D Bonnet and F Dazzi. (2007). Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Leukemia 21:304-310.
57. Secchiero P, S Zorzet, C Tripodo, F Corallini, E Melloni, L Caruso, R Bosco, S Ingrao, B Zavan and G Zauli. (2010). Human bone marrow mesenchymal stem cells display anticancer activity in SCID mice bearing disseminated non-Hodgkins lymphoma xenografts. PLoS One 5:e11140.